The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification ; volume:24 ; number:1 ; day:30 ; month:3 ; year:2024 ; pages:1-11 ; date:12.2024
Cancer cell international ; 24, Heft 1 (30.3.2024), 1-11, 12.2024
- Creator
-
Weng, Lijuan
Zhou, Jianliang
Guo, Shenchao
Xu, Nong
Ma, Ruishuang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03261-0
- URN
-
urn:nbn:de:101:1-2406171042254.167837430763
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Weng, Lijuan
- Zhou, Jianliang
- Guo, Shenchao
- Xu, Nong
- Ma, Ruishuang
- SpringerLink (Online service)
Other Objects (12)
Triple-negative breast cancer molecular subtyping and treatment progress
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
Analysis of CXCL11 expression in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC)
BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells
Triple-negative breast cancer molecular subtyping and treatment progress
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
Analysis of CXCL11 expression in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC)
BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells
Triple-negative breast cancer molecular subtyping and treatment progress
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
Analysis of CXCL11 expression in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC)